Kiniksa Pharmaceuticals International, plc Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Kiniksa Pharmaceuticals International, plc (KNSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 213.49 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2024-02-28
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 213.49K shares, a 42.56% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 371.68K shares, a 64.57% increase from fiscal 2021.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2021 was 225.85K shares, a 274.67% increase from fiscal 2020.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2020 was 60.28K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|
| 2023-12-31 | 213.49K shares 10-K · filed 2024-02-28 |
| 2022-12-31 | 371.68K shares 10-K · filed 2023-03-02 |
| 2021-12-31 | 225.85K shares 10-K · filed 2022-02-24 |
| 2020-12-31 | 60.28K shares 10-K · filed 2021-02-25 |